Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Passage BIO, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 59 | 56 | −3 |
| Shares | 35.5M | 33.4M | −2.18M (−6.1%) |
| Value | $34.0M | $31.4M | −$2.64M (−7.8%) |
New holders (8)
Institutions that held Passage BIO, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Acuitas Investments, LLC | 418,173 | $393.6K | 0.23% |
| Pale Fire Capital SE | 98,662 | $92.9K | 0.01% |
| Squarepoint Ops LLC | 69,712 | $65.6K | 0.00% |
| Cresset Asset Management, LLC | 23,725 | $22.3K | 0.00% |
| Two Sigma Securities, LLC | 20,608 | $19.4K | 0.00% |
| Steward Partners Investment Advisory, LLC | 1,010 | $951 | 0.00% |
| Rhumbline Advisers | 783 | $736 | 0.00% |
| First Capital Advisors Group, LLC. | 23 | $22 | 0.00% |
Sold out (11)
Institutions that held Passage BIO, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Newtyn Management, LLC | 665,221 | $637.1K |
| Gsa Capital Partners LLP | 130,188 | $125.0K |
| Connor, Clark & Lunn Investment Management Ltd. | 82,895 | $79.4K |
| Vontobel Holding Ltd. | 80,000 | $76.6K |
| Occudo Quantitative Strategies LP | 27,758 | $26.6K |
| HRT Financial LP | 19,723 | $18.0K |
| Dimensional Fund Advisors LP | 18,114 | $17.3K |
| Jane Street Group, LLC | 16,568 | $15.9K |
| Cubist Systematic Strategies, LLC | 10,129 | $9.70K |
| Point72 Asset Management, L.P. | 89 | $85 |
| Simplex Trading, LLC | 318 | $0 |